Business Context and Reporting Period
This Form 8-K was filed by AYTU BIOSCIENCE, INC. on April 22, 2016. The filing primarily reports the entry into a material definitive agreement to acquire exclusive U.S. rights to Natesto (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, effective upon the expiration of the current licensee's rights on June 30, 2016. The filing also includes preliminary unaudited financial estimates for the quarter ended March 31, 2016.
Key Financial Metrics
- Revenue (Q1 2016 Estimate): Approximately $669,000.
- Cash and Cash Equivalents (as of March 31, 2016): Approximately $8,666,000.
- Upfront Payments: $2,000,000 paid immediately; $2,000,000 due September 5, 2016; $4,000,000 due January 1, 2017.
- Stock Purchase: Purchase of 12,245,411 shares of Acerus common stock for approximately $2,000,000 (Cdn. $2,534,800).
- Maximum Milestone Payments: Up to $37,500,000 contingent on net sales thresholds.
- Profit and Margins: The filing text does not provide clear values for net income, profit margins, or operating expenses.
- Debt and Liquidity: The filing notes a material non-cash expense related to derivative features triggered by convertible debt conversion during the quarter. Specific debt balances are not disclosed.
Material Changes Versus Prior Period
- Revenue Growth: Estimated revenue for the quarter ended March 31, 2016, grew 42% quarter-over-quarter compared to $469,000 for the quarter ended December 31, 2015.
- Cash Position: Cash and cash equivalents decreased from $10,960,000 at December 31, 2015, to approximately $8,666,000 at March 31, 2016.
- Strategic Acquisition: The company entered a new license and supply agreement for Natesto, a significant change in its product portfolio and operational scope.
Guidance, Outlook, and Risks
- Financial Estimates: The financial data provided for Q1 2016 is preliminary, unaudited, and based on estimates. Actual results may differ materially upon completion of financial closing procedures.
- Non-Cash Expenses: Management anticipates a material non-cash expense related to derivative features triggered by convertible debt conversion in Q1 2016.
- Operational Commitments: AYTU is responsible for managing the NDA, regulatory compliance, and a cardiovascular postmarketing requirement (PMR), though Acerus must reimburse PMR costs.
- Termination Risks: AYTU may terminate the agreement with six months' notice but remains liable for certain upfront and milestone payments. Acerus may terminate if PMR reimbursement obligations render the agreement economically unviable.
- Supply Pricing: Supply prices are tied to Acerus's cost of goods sold (115%) plus a percentage of net selling price (ranging from 10% to 25%), subject to a fixed ceiling price.
Investor Verification Checklist
- Verify the final audited financial results for the quarter ended March 31, 2016, to confirm the estimated revenue of $669,000 and the impact of the non-cash derivative expense.
- Confirm the exact timing and conditions for the transfer of Natesto rights from the current licensee (Endo) to AYTU on June 30, 2016.
- Review the full text of the License and Supply Agreement (Exhibit 10.1) to understand the specific "fixed ceiling price" for product supply.
- Monitor the company's cash burn rate given the upcoming $6,000,000 in scheduled upfront payments and the recent decrease in cash reserves.
- Assess the status of the convertible debt conversion and the resulting impact on the company's capital structure.